Bank of New York Mellon Corp Purchases 1,408 Shares of LeMaitre Vascular, Inc. (LMAT)

Bank of New York Mellon Corp boosted its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 1.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 88,552 shares of the medical instruments supplier’s stock after buying an additional 1,408 shares during the period. Bank of New York Mellon Corp’s holdings in LeMaitre Vascular were worth $2,181,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Conestoga Capital Advisors LLC purchased a new position in LeMaitre Vascular during the first quarter valued at approximately $9,549,000. Summit Creek Advisors LLC purchased a new position in LeMaitre Vascular during the first quarter valued at approximately $5,311,000. Thomson Horstmann & Bryant Inc. raised its position in LeMaitre Vascular by 111.3% in the first quarter. Thomson Horstmann & Bryant Inc. now owns 359,339 shares of the medical instruments supplier’s stock valued at $8,850,000 after buying an additional 189,280 shares in the last quarter. Perkins Capital Management Inc. purchased a new position in LeMaitre Vascular during the first quarter valued at approximately $2,677,000. Finally, Russell Investments Group Ltd. raised its position in LeMaitre Vascular by 211.2% in the first quarter. Russell Investments Group Ltd. now owns 150,413 shares of the medical instruments supplier’s stock valued at $3,705,000 after buying an additional 102,078 shares in the last quarter. Institutional investors and hedge funds own 66.35% of the company’s stock.

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) opened at 28.99 on Thursday. The firm has a market capitalization of $545.27 million, a P/E ratio of 48.40 and a beta of 0.63. LeMaitre Vascular, Inc. has a one year low of $14.04 and a one year high of $33.22. The firm has a 50-day moving average of $29.88 and a 200-day moving average of $26.52.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Thursday, May 4th. The medical instruments supplier reported $0.16 EPS for the quarter, topping the Zacks’ consensus estimate of $0.13 by $0.03. The firm had revenue of $24.10 million during the quarter, compared to analyst estimates of $23.48 million. LeMaitre Vascular had a return on equity of 13.36% and a net margin of 12.52%. LeMaitre Vascular’s revenue was up 18.7% on a year-over-year basis. On average, equities analysts predict that LeMaitre Vascular, Inc. will post $0.70 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://sportsperspectives.com/2017/07/20/bank-of-new-york-mellon-corp-purchases-1408-shares-of-lemaitre-vascular-inc-lmat.html.

Several equities research analysts recently weighed in on the stock. Canaccord Genuity reaffirmed a “buy” rating and issued a $28.00 price objective on shares of LeMaitre Vascular in a report on Thursday, April 27th. Stifel Nicolaus upped their price objective on shares of LeMaitre Vascular from $25.00 to $29.00 and gave the stock a “buy” rating in a report on Friday, April 28th. Craig Hallum assumed coverage on shares of LeMaitre Vascular in a report on Tuesday, June 6th. They issued a “hold” rating and a $31.00 price objective for the company. Zacks Investment Research raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $36.00 price objective for the company in a report on Friday, April 28th. Finally, Benchmark Co. downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Monday, July 10th. They noted that the move was a valuation call. Six investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. LeMaitre Vascular presently has a consensus rating of “Hold” and an average price target of $27.00.

In related news, VP Michael T. Wijas sold 2,346 shares of LeMaitre Vascular stock in a transaction dated Thursday, June 1st. The stock was sold at an average price of $31.42, for a total value of $73,711.32. Following the completion of the sale, the vice president now directly owns 3,584 shares in the company, valued at $112,609.28. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Chairman George W. Lemaitre sold 87,342 shares of the firm’s stock in a transaction dated Wednesday, May 3rd. The stock was sold at an average price of $32.35, for a total value of $2,825,513.70. Following the transaction, the chairman now owns 3,484,149 shares in the company, valued at approximately $112,712,220.15. The disclosure for this sale can be found here. Over the last quarter, insiders sold 317,805 shares of company stock valued at $9,910,332. Corporate insiders own 23.70% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMAT).

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply